Johnson & Johnson cited the COVID-19 outbreak and declining demand in announcing this week it would discontinue sales of its talcum powder-based baby powder, but lawyers attributed the move to a court decision one month ago that allowed plaintiffs’ experts to testify in potentially tens of thousands of lawsuits.
Johnson & Johnson’s May 19 announcement, which follows years of jury verdicts in cases alleging its talcum powder products caused ovarian cancer and mesothelioma, attributed the timing to a “portfolio assessment related to COVID-19.” Johnson & Johnson also cited declining demand caused by misinformation about the safety of its baby powder and a “constant barrage of litigation advertising.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
